Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076089 · ClinicalTrials.gov registry record · Phase 3
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
A Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT00076089 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD that has completed, run by AstraZeneca. The registered enrollment target is 1,100 participants, below the 1,741-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 20 states.
The verdict
NCT00076089, a Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Roflumilast
Study Locations (20)
Alabama
- ALTANA Pharma - Cities in Alabama
Arizona
- ALTANA Pharma - Cities in Arizona
Arkansas
- ALTANA Pharma - Cities in Arkansas
California
- ALTANA Pharma - Cities in California
Colorado
- ALTANA Pharma - Cities in Colorado
Connecticut
- ALTANA Pharma - Cities in Connecticut
Florida
- ALTANA Pharma - Cities in Florida
Georgia
- ALTANA Pharma - Cities in Georgia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076089
The ClinicalTrials.gov registry entry for NCT00076089 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,741-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (37% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Roflumilast is the first listed.
NCT00076089 reports 20 study locations spanning 20 distinct geographic areas - top geographies include Alabama, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00076089 about?
NCT00076089 is a clinical study titled "OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)". The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00076089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2003-12. Estimated completion is 2005-12.
What conditions does trial NCT00076089 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD.
What interventions are being tested in trial NCT00076089?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT00076089?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076089 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.